Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 4/20 | 0.55 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.55 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.55 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.55 |
| ▸ | CTSC | P53634 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 3/20 | 0.46 |
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26506585 | 0.90 | ULK1 (0.55) | ULK1PRKAA2PRKAA1ULK2CTSC | |
| SCHEMBL26506551 | 0.90 | ULK1 (0.61) | ULK1PRKAA2PRKAA1ULK2EGFR | |
| SCHEMBL26506588 | 0.89 | ULK1 (0.55) | ULK1PRKAA2PRKAA1ULK2SYK | |
| SCHEMBL26506559 | 0.87 | ULK1 (0.54) | ULK1PRKAA2PRKAA1ULK2EGFR | |
| SCHEMBL26506579 | 0.87 | ULK1 (0.59) | ULK1PRKAA2PRKAA1ULK2EGFR | |
| SCHEMBL26506589 | 0.87 | ULK1 (0.59) | ULK1PRKAA2PRKAA1ULK2EGFR | |
| SCHEMBL26506580 | 0.86 | ULK1 (0.58) | ULK1PRKAA2PRKAA1ULK2EGFR | |
| SCHEMBL26506572 | 0.84 | ULK1 (0.56) | ULK1PRKAA2PRKAA1ULK2SYK | |
| SCHEMBL26506558 | 0.84 | ULK1 (0.56) | ULK1PRKAA2PRKAA1ULK2SYK | |
| SCHEMBL26506581 | 0.84 | ULK1 (0.56) | ULK1PRKAA2PRKAA1ULK2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135635-A1 | INHIBITORS OF ULK1/2 AND METHODS OF USING SAME | Sanford Burnham Prebys Medical Discovery Institute | 2023-05-04 | — | — | US | disclosed |
| US-20230135635-A1 | INHIBITORS OF ULK1/2 AND METHODS OF USING SAME | Sanford Burnham Prebys Medical Discovery Institute | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135635-A1 | INHIBITORS OF ULK1/2 AND METHODS OF USING SAME | ULK2, ULK1, ULK3 | ULK1 2/4885PRKAA2 130/4885PRKAA1 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.